Skip to main content

Here's how much top biotechs spent on R&D last quarter

Some of Massachusetts' largest biotechs spent a substantial portion of their first-quarter expenses on R&D — upwards of 75 percent among commercial companies and 87 percent among clinical-stage companies, according to data compiled by the Business Journal.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.